Infliximab biosimilar
Showing 1 - 25 of 553
Hidradenitis Suppurativa Trial in Lahore (Infliximab biosimilar)
Active, not recruiting
- Hidradenitis Suppurativa
- Infliximab biosimilar
-
Lahore, Punjab, PakistanServices Institute of Medical Sciences
Dec 22, 2022
Medicine Called Infliximab[Infliximab Biosimilar 3] in People
Not yet recruiting
- Arthritis, Rheumatoid
- +3 more
- (no location specified)
Mar 31, 2023
Ankylosing Spondylitis, Axial Spondyloarthritis Trial (Adalimumab and its biosimilars, Biological: Etanercept and its
Not yet recruiting
- Ankylosing Spondylitis
- Axial Spondyloarthritis
- Adalimumab and its biosimilars
- +3 more
- (no location specified)
Dec 6, 2021
Switch From Original Infliximab to Its Biosimilar in Daily
Completed
- Rheumatoid Arthritis
- +3 more
- Switch from REMICADE® to INFLECTRA®
-
Paris, FranceHôpital Cochin
Apr 30, 2021
Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Crohn´s
Completed
- Crohn´s Disease
-
Innsbruck, Austria
- +17 more
Jun 15, 2021
Crohn's Disease Trial in Seoul (Infliximab-Dyyb)
Not yet recruiting
- Crohn's Disease
-
Seoul, Korea, Republic ofAsan Medical Center
Oct 5, 2023
IBD Trial in Paris (Biocollection)
Not yet recruiting
- Inflammatory Bowel Diseases
- Biocollection
-
Paris, FranceSaint Antoine Hospital Service de Gastroentérologie et Nutrition
Feb 1, 2023
Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease Trial (TDM-based infliximab intravenous therapy, Standard
Not yet recruiting
- Crohn Disease
- +4 more
- TDM-based infliximab intravenous therapy
- Standard infliximab intravenous therapy
- (no location specified)
Sep 26, 2023
On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
Completed
- Crohn Desease
- +4 more
- QOL questionaire
-
Strasbourg, Alsace, France
- +67 more
Feb 4, 2022
EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM
Recruiting
- Inflammatory Bowel Diseases
- Rheumatologic Disease
-
Milano, ItalyIrccs Ospedale San Raffaele
Jan 30, 2023
A 24-month Real Life PErsistence Efficacy and Safety Study in
Recruiting
- Inflammatory Bowel Diseases
- Subcutaneous infliximab CT-P13 Remsima®SC
-
Grenoble, FranceNicolas Mathieu
Aug 2, 2022
Theranostic Test to PREDict Treatment Response of Anti-TNFa
Terminated
- RheumatoId Arthritis
- Infliximab
- +6 more
-
Prague, Czechia
- +7 more
Dec 21, 2019
Crohn Disease Trial (Azathioprine + infliximab, Intestinal resection)
Not yet recruiting
- Crohn Disease
- Azathioprine + infliximab
- Intestinal resection
- (no location specified)
Oct 14, 2022
Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
Completed
- Rheumatoid Arthritis
- Biosimilar Infliximab
-
Amman, Jordan
- +1 more
Mar 3, 2020
Cytokines and Genes in Therapeutic Response in Crohn's Disease
Completed
- Inflammatory Bowel Diseases
- Baseline blood sample
- +6 more
-
Nashville, Tennessee
- +1 more
May 4, 2022
Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
Not yet recruiting
- Rheumatoid Arthritis
- +2 more
- collection of clinical parameters and blood sample
-
Paris, IDF, FranceRheumatology Department, Cochin Hospital
Jun 17, 2022
Crohn Disease Trial in Cincinnati (RoadMAB)
Recruiting
- Crohn Disease
- RoadMAB
-
Cincinnati, OhioCincinnati Children's Hospital
Oct 19, 2021
Rheumatoid Arthritis (RA) Trial in Worldwide (NI-071, Infliximab)
Completed
- Rheumatoid Arthritis
-
Little Rock, Arkansas
- +133 more
Jan 26, 2023
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Trial in Toulouse (Remsima IV, Remsima SC)
Recruiting
- Rheumatoid Arthritis
- +3 more
- Remsima IV
- Remsima SC
-
Toulouse, FranceCHU Purpan Hôpital Pierre Paul Riquet
May 17, 2023
IBD, Crohn Disease, Ulcerative Colitis Trial (Infliximab)
Not yet recruiting
- Inflammatory Bowel Diseases
- +2 more
- (no location specified)
Oct 27, 2023
Axial Spondyloarthritis Trial (Tapered doses of TNFi, Standard dose of TNFi)
Recruiting
- Axial Spondyloarthritis
- Tapered doses of TNFi
- Standard dose of TNFi
-
Toronto, Ontario, CanadaUniversity Health Network - Toronto Western Hospital
Nov 21, 2022